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Dyskinetic disorders are characterized by excess of motor activity that may interfere with normal movement control. In patients
with Parkinson’s disease, the chronic levodopa treatment induces dyskinetic movements known as levodopa-induced dyskinesias
(LID). This paper analyzed the pathophysiology, clinical manifestations, pharmacological treatments, and surgical procedures
to treat hyperkinetic disorders. Surgery is currently the only treatment available for Parkinson’s disease that may improve both
parkinsonian motor syndrome and LID. However, this paper shows the diﬀerent mechanisms involved are not well understood.
1. Introduction
Hyperkinetic or dyskinetic disorders are characterized by
excessive muscular activity that may interfere with nor-
mal movement control. Dyskinesias include diﬀerent types
of movement disorders such as chorea-ballism, dystonia,
myoclonus, tics, and tremor. In patients with Parkinson’s dis-
ease (PD), chronic levodopa treatment may induce various
dyskinetic movements (levodopa induced dyskinesias (LID))
which are classified according to the phenomenology and
also their temporal presentation in relation with the eﬀect
of levodopa.
The association between levodopa and the induction of
dyskinesias was recognized soon after the introduction of
levodopa [1, 2]. In the past, levodopa therapy was associated
with the development of motor complications in about 80%
of patients within 5 years of treatment [3, 4]. In patients
with young onset PD, the incidence of LID was higher and
ensued more rapidly [2, 5]. Currently, with the introduction
and widespread use of dopaminergic agonists, the overall
treatment exposure to levodopa is decreasing, especially in
the first years of treatment; nevertheless, progression of the
nigrostriatal deficit will facilitate the onset of LID at a later
point in time. Thus, LID continues to be a common and
important cause of disability in PD and one of the main
reasons for recommending surgical treatment.
In this paper we describe the major clinical features,
main pathophysiological and pharmacological abnormalities
associated with LIDs, and the drug and surgical treatments
currently available.
2. Clinical Presentation
LID may be divided into various presentation forms
(Figure 1) [6].
(1) “Peak dose” or “on” period dyskinesia related to high
plasma levels of levodopa, in parallel with the max-
imal antiparkinsonian benefit. These are typically
choreic in nature and predominantly involve the
neck, trunk, and upper limbs, but dystonic move-
ments may also occur.
(2) Diphasic dyskinesia appears at the onset and oﬀset
of the levodopa eﬀect, coinciding with arising and
decaying plasma levodopa levels. This is character-
ized by repetitive and stereotyped repetitive, slow
(<4Hz) movements of the lower limbs often coin-
ciding with 4Hz tremor in the upper limbs [4],
indicating the patient is not fully “on”. In severe cases,
the movements of the legs may lose the repetitive and
stereotypic nature and resemble ballism. In a small
proportion of patients, diphasic dyskinesias are very
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Figure 1: Relationship between LID and DOPA plasma level. “Peak
of dose” or “on” period dyskinesia is correlated to high level of
levodopa and in parallel with the maximal clinical benefit. Diphasic
dyskinesia appears at the onset and oﬀset of the levodopa eﬀect in
relationship with increment or decrement of plasma level. “Oﬀ”
period dystonia is characterized by painful postures in lower
extremities and is correlated with the lowest levodopa level.
Generally a full spectrum of the three types is present in patients
with motor fluctuations.
prominent while walking, drastically interfering with
gait, and giving rise to a picturesque pattern [7]. Dys-
tonic posture may also occur, although much less
frequently.
(3) “Oﬀ” period dystonia, characterized by fixed and
painful postures more frequently aﬀecting the feet,
but which can be segmental or generalized in distri-
bution.
A combination of any of these 3 types or indeed, all
of them, may be observed in some patients throughout the
levodopa (“oﬀ-on-oﬀ”) cycle. Until now LID, by definition,
were associated with levodopa intake and, to a much lesser
extent, with dopamine agonists used in monotherapy. Two
more recent situations whereby dyskinesias can be induced
in patients with PD despite not being treated with dopamin-
ergic drugs are (1) patients treated with fetal cell transplants
[8]; (2) patients treated with deep brain stimulation (DBS)
of the subthalamic nucleus (STN) [9]. The former has no
practical implications as experimental trials with fetal cell
transplants are not a therapeutic option, but STN-DBS is
fairly frequently applied. In the latter instance, adjusting the
current parameters usually results in control of dyskinesias.
3. Pathophysiology of LID
Levodopa is converted into dopamine (DA) in many brain
regions and “a priori” there are several sites where its
dyskinesogenic eﬀect could occur. The striatal origin of LIDs
was suspected as soon as the problem was recognized in the
early 1970’s but there were no experimental or clinical proofs.
Direct proofs arose unexpectedly when fetal mesencephalic
cells transplanted into the striatum in experimental trials for
PD were associated with dyskinesias with a similar clinical
pattern than LID [10, 11].
Two main factors are involved in the origin of LID. (1)
Degree of dopaminergic nigro-striatal depletion, which is
related to disease duration and severity. (2) The pharmacoki-
netics and mechanism of action of levodopa, which delivers
a discontinuous or pulsatile stimulation of dopaminergic
receptors [3, 12]. Together, degree of nigro-striatal lesion
and the action of levodopa interact to induce changes in
corticostriatal transmission and plastic synaptic abnormal-
ities in striatal spiny neurons, which ultimately may alter
the physiological activity of striatopallidal circuits, leading to
abnormal pattern of neuronal activity underlying LID [13,
14]. A direct demonstration of the link between short acting
dopaminergic stimulation and changes in basal ganglia
output was provided several years ago. It was shown that
once or twice a day levodopa or apomorphine administration
in parkinsonian monkeys induced dyskinesias which were
associated with a reduction in the main firing frequency
of globus pallidus internus (GPi) neurons [15, 16]. Similar
results have been described in parkinsonian patients who
were administered apomorphine during pallidal surgery.
Here, the turning from the “oﬀ” parkinsonian condition
to the “on” mobile state plus LID was associated with a
significant reduction in the mean neuronal firing rate of the
GPi and STN [17–19]. In addition, STN and GPi activity
was decreased when assessed by regional brain uptake of 2-
deoxyglucose, which measures aﬀerent synaptic activity, in
MPTP monkeys with dyskinesias induced by dopaminergic
drugs [20]. Thus, reduced GPi inhibitory output activity
to the thalamus leads to disinhibition of the thalamo-
cortical projection, facilitating the abnormal recruitment of
cortical motor areas which ultimately give rise to dyskinetic
movements. In simple terms therefore, dyskinesias in general
and LID in particular may be understood as the reverse of the
parkinsonian state, whereby the latter is mainly characterized
by overactivity of the STN and GPi output, leading to over-
inhibition of the thalamus and decreased thalamocortical
activity (Figure 2) [20–24].
The metabolic activity reduction and firing reduction
and firing frequency changes in firing pattern of GPi activity
to the thalamus are thought to produce an increase in
thalamocortical drive leading to dyskinesia.
Which striatopallidal circuits, if any, may be preferen-
tially mediate LID has been a matter of discussion over the
years. D2 mediated activation of the striato-pallidal projec-
tions in the “indirect” basal ganglia circuit was favored for
a long time. Thus, pharmacological manipulation of the
“indirect” circuit induces dyskinesias in monkeys which are
similar to LID. For example, this is achieved by injecting
bicuculline, a γ-amino butyric acid (GABA) antagonist into
the globus pallidus externus (GPe), which results in increased
GPe eﬀerent activity and overinhibition of the STN [25] or by
blocking STN glutamatergic projection, which provokes GPi
neuronal hypoactivity and involuntary movements in the
monkey [26, 27]. Moreover, it is well known that STN lesion
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Figure 2: Classic model of basal ganglia in normal condition, parkinsonian, and dyskinetic conditions. During LID the diﬀerent population
of striatal cells from direct and indirect circuit are opposite to parkinsonian state. LID would result from a decrease in the inhibitory pathway
by striatal neurons in the indirect pathway to the GPe, leading to an inhibitory increment over the STN and consequently reducing STN and
GPi/SNr activity. This is facilitated by the increase in the inhibitory striatal activity of GPi by the direct pathway from striatum.
induces hemichorea-ballism, and both deep brain stimula-
tion (DBS) and subthalamotomy in PD patients may induce
dyskinesias that are identical to those triggered by levodopa.
On the other hand, more recently molecular changes in the
striatum and the eﬀects of some dopaminergic drugs have
suggested, that LID are mediated by D1 receptor activation
in the “direct” circuit [28, 29]. Thus, increased activity in the
signaling by activation of D1 receptors has been encountered
both in animal models and PD patients with LID [30–33]. D1
receptor is abnormally abundant at the plasma membrane
of striatal neurons and it seems to be dysregulated in LID
by alterations in intraneuronal traﬃcking [34]. In addition,
some interesting findings have suggested a relevant role for
D3 receptor in the pathophysiology of LID [35, 36].
It is also important to consider the changes related
to glutamatergic striatal input. The striatum receives mas-
sive cortical and thalamic glutamatergic inputs, which are
increased in the parkinsonian state [37]. This has been
suggested as the mechanism mediating loss of spines in
medium spiny neurons [38], which in turn could render
the striatum vulnerable to large changes in dopamine avail-
ability following levodopa treatment in PD. Recent evidence
suggests that the expression, proportion and location of
striatal NMDA glutamate receptors may play a paramount
role in the molecular mechanisms mediating LID. In the
6-hydroxydopamine (OHDA) rat model it has been shown
that the ratio of NR2b/NR2a is increased and there is a shift
to the extra-synaptic space of the NR2b receptor subunit in
dyskinetic rats [39].
Recently, optogenetics was applied to selectively block
the protein DARPP-32 in medium spiny neurons of the
“direct” striatonigral projection, resulting in marked LID
reduction in the rat model, whereas blockade of striatopal-
lidal neurons giving rise to the “indirect circuit” produced a
robust increase in locomotors activity and reduced cataleptic
response to haloperidol [40].
Finally, dopaminergic drugs act not only in the striatum
but also on other basal ganglia nuclei, the thalamus and cor-
tex, all of which are dopamine depleted in variable extent in
PD. The possible action of levodopa and other dopaminergic
drugs modulating firing activity of the GPe, GPi and STN
should not be underestimated and is still pending definitive
studies.
Altogether, there is increasing evidence that overlapping
mechanisms underlie the appearance of LID. They seem to
converge in alterations of the striatal synaptic function in
response to the loss of dopaminergic input and to subsequent
replacement of dopamine by pharmacological means [29].
This concept, defined as striatal plasticity, occurs through
functional processes such as long term potentiation, long
term depression, or a maladaptive form of plasticity invoked
as depotentiation [33, 41]. In the presence of exogenous
levodopa, distinct patterns of synaptic aberrant plasticity
developed in both the direct and indirect pathways, and
so a new perspective is open whereby LID in PD could be
considered as a network disorder [42]. Indeed, two recent
studies comparing LID versus non-LID groups of patients
found an increase in the structural signal of the gray-matter
focused on the inferior frontal gyrus (IFG) particularly in the
right hemisphere, whereas a functional MRI study pointed
to an increased task-related activity in the supplementary
motor area and reduced activity in the right IFG. These data
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suggest that changes in the right IFG reflect neuroplasticity
following from years of increased use of executive control to
override involuntary movements in LID [43].
In conclusion, the dopaminergic system controls the
excitability of the striatum and other basal ganglia nuclei
leading to modulation of neuronal firing rates and patterns.
LID may originate in striatal spiny neurons, mainly in the
putamen leading to reduced mean discharge rate, abnormal
firing pattern, and pathological oscillatory activity that
are transmitted throughout striatopallidal projection to the
thalamocortical projection.
4. LID Pharmacological Treatments
Threemain therapeutic strategies have been used to treat LID
in PD.
(1) Prevention of LID development by early use of
dopamine agonist drugs and reduced levodopa dose
intake at the beginning of treatment.
(2) Symptomatic treatment, once LID developed, with
putative antidyskinetic interventions.
(3) Reverting dyskinesias by continuous dopaminergic
stimulation to achieve a wider therapeutic window,
reducing “oﬀ” hours while improving dyskinesias.
4.1. Prevention of LID. The use of neuroprotective drugs to
slow disease progression has been extensively explored. L-
deprenyl(selegiline), in an extension of the DATATOP study,
failed to produce a significant reduction in the incidence of
dyskinesias [44].
The only group that has demonstrated to some extent
a reduction in the risk of developing dyskinesias is the
dopamine agonists. Several placebo-controlled studies com-
pared the evolution of patients initiated with a dopamine
agonist (ropinirol, pramipexol, and cabergoline) and stan-
dard levodopa. Rascol et al. in a comprehensive, double-
blind parallel study, compared the eﬃcacy of ropinirol and
levodopa over a period of 5 years in 268 patients with early
PD [5]. The analysis of the time to onset of dyskinesia showed
a significant diﬀerence in favor of ropinirol. The cumulative
incidence of dyskinesia at fifth year, regardless of levodopa
supplementation, was 20% in the ropinirol group and 45%
in the levodopa group. The mean daily dose of ropinirol
was 15mg but the majority of the patients enrolled in that
group required supplementary treatment with levodopa [5].
When patients receiving ropinirole monotherapy required
the addition of levodopa, the risk of developing dyskinesias
increased, and eventually, during followup, did not diﬀer
significantly from that associated with levodopa alone [45].
The use of ropinirole as monotherapy with only later addi-
tion of levodopa over 10-year follow-up delayed the onset of
dyskinesias by up to 3 years [46]. Moreover, the prolonged-
release form of ropinirole recently demonstrated a delay in
the onset of dyskinesias compared with increasing doses
of levodopa [47]. These clinical observations under control
conditions confirmed experimental data in the MPTP mon-
key showing that ropinirol alone or in combination with
low-dose levodopa delayed dyskinesia onset while improving
motor performance [48].
The CALM-PD was a randomized controlled trial that
evaluated the risk of developing dyskinesias in patients with
early PD treated initially with either pramipexole or lev-
odopa, followed by a maintenance phase during which open-
label levodopa-carbidopa was permitted as needed [49].
After 24 months, pramipexole-treated patients were receiv-
ing a mean daily dose of 2.78mg pramipexole plus 264mg
levodopa, compared with 509mg levodopa for those receiv-
ing only this agent. There were fewer pramipexole-treated
patients that reached the primary endpoint of time to first
occurrence of wearing oﬀ, dyskinesias, or on-oﬀ motor fluc-
tuations (27.8% versus 50.7%). Patients in the pramipexole
group also had a significantly lower incidence of dyskinesias
(9.9% versus 30.7%) [49]. After a mean 6-year follow-up,
over 90% of patients ended up receiving levodopa therapy
regardless of their initial treatment assignment. Compared
to those taking pramipexole, patients initially treated with
levodopa had significantly more dyskinesias (20.4% versus
36.8%), but there was no diﬀerence in the incidence of
disabling or painful dyskinesias [50].
The ergot derivativecabergoline holdsa long half-life
(≈72 hours) and therefore may be administered once daily.
In a double-blind multicenter trial on 419 patients naive
to treatment, comparing cabergoline and levodopa as initial
therapy for PD, motor complications were significantly
delayed and occurred less frequently in cabergoline-treated
patients compared to levodopa-treated patients [51].
An evidence-based review compared the results of studies
published on early treatment of PD with dopamine agonists
with similar studies using levodopa [52]. Cabergoline, pram-
ipexole, and ropinirol were similarly eﬀective in reducing
the risk of LID, although reduction was slightly greater for
pramipexole and ropinirol than for cabergoline. The latter
is no longer used widely because of the associated risk of
cardiac valvulopathy [53].
A concern encountered in the three studies was that,
whereas treatment with a dopamine agonist reduced the risk
of dyskinesia, this was associated with less antiparkinsonian
benefit. Currently, three dopamine agonists provide longer
stimulation of DA receptors, by delay-release per oral route
(for pramipexol and ropinirole) and transdermal application
(rotigotine). The eﬃcacy of these new dopamine agonists
formulations on LID has not been specifically assessed yet.
It remains also open to future analysis to determine whether
the initial benefit on LID of treatment with a dopamine
agonist is carried forward over the long-term evolution once
levodopa is added to the regimen. In addition, several issues
related to the design of the studies have been raised by critical
voices. Our own view, which is generally shared by most
movement disorder neurologists, is that the severity of LID
observed in clinical practice has been considerably reduced
over the last decade, coinciding with the earlier use of
dopamine agonists and the associated possibility of reducing
levodopa daily dose. Thus, while more definitive data are
being compiled, we favor the prevailing concept of starting
therapy with a dopamine agonist, particularly in patients
who are 65 years old or younger at the time of diagnosis.
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This approach has been tempered by the more recent
realization of a variety of impulse control disorders (ICD)
associated with the use of dopamine agonists.Whether or not
pathological impulsivity in PD patients will be also reduced
by the use of long-acting dopamine agonists, it is too early to
tell. We hope this will be the case by the analogy and shared
pathophysiological mechanisms of LID and ICD [54].
4.2. LID as a Clinical Management Problem: Symptomatic
Treatments. This is the commonest clinical scenario. Patients
have already developed LID and the clinician has to attempt
to control the abnormal movements by adjusting antiparkin-
sonian drugs or adding agents capable of reducing LID
without increasing motor disability. The diﬃculty in achiev-
ing therapeutic eﬃcacy is directly related to the severity
and complexity of PD in each individual subject. Thus,
LID are relatively easy to control when they are mild and
occur in patients with a wide therapeutic window, but may
be diﬃcult or impossible to treat pharmacologically in
advanced patients who exhibit all forms of LID and fall
into severe “oﬀ” episodes when they are not dyskinetic. We
shall review here the diﬀerent individual pharmacological
approaches available to treat LID but commonly, in many
instances of clinical practice one needs to combine several
options aiming to control both fluctuations and dyskinesias.
4.2.1. Dopamine Agonists. Any one of the above mentioned
dopamine agonists may be added with the intention of
reducing levodopa dose and avoiding peak of dose on-
dyskinesias associated with high levodopa plasma levels while
controlling the severity of “oﬀ” motor state. Belanger et al.
first examined the possibility of reducing LID by using
a small dose of cabergoline [55]. During treatment, they
found LID in the levodopa group but not in the levodopa
+ cabergoline group, which suggests that a small dose of a
long-acting D2 agonist combined with low doses of levodopa
could reduce the incidence of LID in patients with PD. This
study supports a commonly applied clinical strategy. The
practical problem in many instances arises when the reduc-
tion in levodopa doses precludes achieving a suﬃciently good
anti-parkinsonian response, a situation poorly tolerated by
most patients.
A partial D2 receptor agonist may represent an interesting
alternative for the treatment of PD and dyskinesias. These
drugs, characterized by having lower intrinsic activity at
the receptor level than full agonists, act as either functional
agonist or antagonist, depending on the levels of endoge-
nous dopamine. Preclamol has a selective dopamine mixed
agonist-antagonist profile for both pre and postsynaptic
receptors. Its action in patients with disabling “on-oﬀ” fluc-
tuations was compared against placebo and subcutaneous
apomorphine [56], showing a mild but significant anti-
akinetic eﬀect which was of lesser magnitude than that
achieved with subcutaneous apomorphine but caused less
dyskinesia. Aripiprazole is an antipsychotic drug showing
partial agonist activity for D2 and 5HT2A, and antagonist for
5HT2A receptors. Lieberman postulated that this drugmay be
able to reduce dyskinesias without enhancing parkinsonism
[57], and a small pilot study was positive, [58]. However
further studies are required to investigate its antidyskinetic
capacity.
4.2.2. Dopamine Antagonists. The use of drugs that block the
dopaminergic system has been a classical approach for the
treatment of dyskinesias in general. D2 antagonists, like
haloperidol, olanzapine, tiapride, and sulpiride, and presy-
naptic dopamine-depleting drugs, like reserpine and tetra-
benazine, have all proven useful in the management of
hemichorea-ballism, tardive dyskinesias, and tics. These
same drugs are also eﬀective in reducing or suppressing LID
in PD, but this is invariably associated with marked motor
worsening after a variable period (ranging from hours to
weeks). In clinical practice, therefore, they are neither useful
nor recommended.
Recent observations increasingly suggest that atypical
neuroleptic drugs, which are able to block D3 receptors
preferentially, can be beneficial for patients with movement
disorders. Oh et al. evaluated the eﬀects of an atypical anti-
psychotic drug which is antagonistic of 5HT2A/C and D2/3
receptors, quetiapine, on motor behavior in the OHDA
lesioned rat, and in MPTP treated monkeys [59]. In uni-
laterally lesioned rats, quetiapine reversed the shortening
of the motor response to levodopa challenge produced by
treatment during 3 weeks with levodopa twice daily. Que-
tiapine also normalized the short-duration response to acute
injection of agonists either for D1 receptor (SKF38392) or
D2(quinpirole) in rats that had received levodopa in chronic
administration. Quetiapine had no eﬀect on parkinsonian
manifestations when given alone to OHDA lesioned rats
or MPTP monkeys, but did substantially reduce LID when
administered together with levodopa. Katzenschlager et al.
assessed the eﬀect of quetiapine on dyskinesias in a double-
blind cross-over study in 9 patients with PD, receiving
diﬀerent doses of quetiapine or placebo at night [60]. On
50mg/day quetiapine, a slight reduction in LID severity was
observed on a visual analog scale but this improvement was
not reflected in the patients’ overall impression of treatment
eﬀect. Durif et al. investigated the eﬃcacy of clozapine in
the treatment of LID in 50 patients during a 10-week,
double-blind, placebo-controlled, multicenter trial. During a
levodopa challenge the maximal LID score was significantly
decreased in the clozapine group (mean dose ≈40mg/day),
which led to the conclusion that clozapine is eﬀective in the
treatment of LID in severe PD [61].
4.2.3. Glutamatergic Antagonists. The N-methyl-D aspartate
(NMDA) receptor is thought to mediate excitotoxicity in
the basal ganglia, but the use of NMDA antagonists in
humans has generally been limited because of adverse eﬀects
associated with a non-selective blockade. Metman et al., in
a double-blind cross-over study, showed that 3 weeks’ treat-
ment with dextrometorphan was able to reduce dyskinesias
by 30–40% while maintaining the response to levodopa.
In recent years amantadine, which is believed to increase
dopamine release from presynaptic uptake sites, has become
popular as an antidyskinetic drug based on its putative anti-
NMDA action [62]. Del Dotto et al. evaluated the eﬀect
of a 2-hour intravenous amantadine or placebo infusion
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against LID in 9 PD patients with motor fluctuations and
severely disabling peak-dose dyskinesias [63]. Intravenous
amantadine acutely improved LID by 50%, without losing
the antiparkinsonian benefit of levodopa along the 5-week,
double-blind cross-over trial. In another study, Luginger et
al. assessed LID severity by self-scoring diaries after oral
levodopa challenges and found them to be reduced by
approximately 50% after amantadine treatment compared
with baseline or placebo control [64]. Further studies also
found a positive eﬀect for amantadine on LID [65, 66].
Moreover, in a recent trial in advanced PD patients receiving
amantadine continuously over 1 year, a withdrawal of
amantadine led to a significant increase of dyskinesias in
those patients when double-blind switched to placebo, while
no change occurred in those maintained on amantadine.
This supports the notion of a sustained antidyskinetic eﬀect
of amantadine beyond one year of therapy. Our own view
is that, on an individual basis, amantadine may result in a
drastic amelioration of LID and is therefore worth trying in
the absence of contraindications. The antidyskinetic eﬀect is
probably exerted at the level of the STN as amantadine failed
to control dyskinesias evoked by subthalamotomy in patients
who had previously responded markedly well [67].
Merello et al. evaluated the eﬃcacy of memantine on the
pharmacological response to levodopa and the induction of
LID [68]. In 12 patients, in opposition to recent findings with
amantadine, no eﬀect on LID was observed. Nevertheless,
several reports described a benefit of memantine in PD
patients with cognitive impairment and LID with regard to
dyskinesia control [69, 70]. No eﬀect was found for riluzole
on LID [71, 72]. In general, the high expectations that were
raised with the potential therapeutic impact of antigluta-
matergic drugs for PD have so far been disappointed.
4.2.4. Drugs Acting on the Serotoninergic System. The sero-
toninergic system projects quite profusely to the striatum
and also to other key basal ganglia nuclei (i.e., STN, GPe,
GPi), exerting an inhibitory eﬀect on dopamine striatal
transmission. Durif et al. found a 47% improvement in LID
severity induced by apomorphine in 7 patients with PD
treated with fluoxetine [73], out of any reduction in anti-
parkinsonian benefits. Buspirone has a complex mechanism
of action, which aside from its 5HT1A properties includes
partial dopamine agonism and mild opiate and noradren-
ergic antagonism [74]. Bonifati et al. in a double-blind,
placebo-controlled, cross-over study, found that buspirone
significantly lessened the severity of LID in 5 out of 7
patients [75]. Meco et al., in an open-label study including
20 parkinsonian patients, found that mirtazapine, an α2
antagonist, 5HT1A agonist, and 5HT2 antagonist, may be
eﬀective in reducing LID [76].
4.2.5. Drugs Acting on the Opioid System. The opioid striatal
neurons may play a role in the induction of dyskinesias. In
MPTPmonkeys Samadi et al. investigated the eﬀect of diﬀer-
ent doses of naloxone and naltrexone (opioid receptor anta-
gonists) on the dyskinetic response to the D1 agonist SKF-
82958, the D2 agonist quinpirole and levodopa [77]. They
found that joint administration of naloxone or naltrexone
together with dopaminergic agents led to a significant
reduction in the severity of dyskinesias without reducing
antiparkinsonian eﬃcacy. Recently, the selective μ opioid
antagonist ADL5510 provided almost complete alleviation
of LID without compromising reversal of parkinsonian
disability in the MPTP lesioned macaque model of PD [78].
In PD patients, Carroll et al. conducted a placebo-controlled,
double-blind, cross-over trial to examine the potential eﬀect
of cannabis on LID in PD [79]. Seventeen patients completed
the trial and cannabis was well tolerated with no pro- or
anti-parkinsonian action, but there was no evidence of a
treatment eﬀect on LID. Thus, despite many experimental
suggestions, there is no drug currently employed clinically to
manipulate the opioid system for the treatment of LID.
4.2.6. Noradrenergic Drugs. The close relationship between
the dopaminergic, adrenergic and noradrenergic systems has
led to the assessment of a possible antidyskinetic eﬀect of a
few drugs acting on those systems. Carpentier et al. found
a significant 40% improvement in dyskinesia scores in PD
patients treated with a low dose of propranolol [80]. Other
studies have shown how the α2 adrenoreceptor antagonist
idazoxan can significantly reduce LID in monkey and rat
models as well as in advanced PD patients [81, 82]. Rascol
et al. reported improvement of LID without reappearance
of parkinsonian symptoms in 18 patients treated with
idazoxan [83]. Another α2 antagonist, fipamezole, reduced
the severity of LID by 23% and 31% at 60mg, and 90mg
respectively, without aﬀecting antiparkinsonian response.
Currently, further trials are being carried out [84].
4.2.7. Adenosine A2A Antagonists. Adenosine A2A receptors
are found in the striatum and thalamus and colocalize with
dopamine D2 receptors. Adenosine A2A antagonists regulate
dopamine and glutamate release in the brain, and they may
improve motor symptoms as novel compensatory mode for
loss of dopamine signaling with associated NMDA antago-
nism [85]. The trials target symptoms associated with
dopamine replacement and therapy of dyskinesia, such as
istradefylline [86, 87]. However, recent trial outcomes show-
ed that istradefylline did not improve motor behavior or
“oﬀ” times in PD patients compared with earlier results [88–
92]. Preladenant showed, in a phase II placebo-controlled
dose-ranging trial of 253 PD patients receiving stable dopa-
minergic therapy, an increase in awake time spent in the on-
state of 1.4 h/day compared to 0.2 h/day in the placebo group,
without overall worsening of dyskinesias [93]. The long-term
antidyskinetic eﬀect of preladenant needs ascertainment.
4.2.8. Other Drug Treatments. Levetiracetam, an antiepilep-
tic drug, has been evaluated against LID with mixed results
in several open-label studies [94–98]. The most promising
data come from a study of 9 patients experiencing LID for
at least 25% of waking hours [98]. After 60 days treat-
ment with a mean of 625mg of levetiracetam, patients
experienced a 42% increase in the “on” time without LID
or with nontroublesome dyskinesia in absence of signif-
icant change in the “oﬀ” time. Pardoprunox is a mixed
dopamine agonist/antagonist D2 and D3, and a full agonist
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at 5HT1a receptors. It also binds with lower aﬃnity to D4,
α1 adrenergic, and 5HT7 receptors [99, 100]. Due to its
unique pharmacologic profile, pardoprunox might have a
lower tendency than other dopaminergic therapies to cause
dyskinesias or neuropsychiatric side eﬀects [93, 99–101].
Safinamide is an antiparkinsonian agent that is also in advace
state of development to reach clinical practice. It has a dual
mechanism of action, as it is a MAOB inhibitor and also
reduces overactivity of glutamatergic signaling by inhibiting
glutamate release [102, 103]. On this prospection, AFQ056
recently achieved a significant and relevant antidyskinetic
clinical eﬀect without reducing the antiparkinsonian benefits
of dopaminergic therapy [104]. Recently, low-frequency
transcranial magnetic stimulation has also been applied
to the treatment of LID, showing transient experimental
improvements in preliminary study [105].
4.2.9. Practical Considerations. There appear to be many
drugs that are capable of reducing LID severity. In occasional
patients the therapeutic impact of any one of the treatments
summarized above may be strikingly positive, but in the
majority of patients it is limited to mild and short-lasting
improvement. Nevertheless, these treatments are generally
well tolerated and worth trying, when available, in patients in
whom other therapeutic measurements cannot be aﬀorded.
In our experience, the degree of symptomatic control of
LID mainly depends upon the complexity of dyskinesias and
severity of “oﬀ” periods. This may be schematically summa-
rized as follows: (1) in patients with mild but bothersome
peak-dose dyskinesias, readjust the levodopa schedule, and
consider adding a dopamine agonist. If this approach fails,
any one of the drugs discussed above may be tried out;
(2) for patients with intense peak-dose dyskinesias, consider
switching treatment to provide continuous dopaminergic
stimulation; (3) patients with severe peak-dose dyskinesias
and diphasic dyskinesias probably require surgical treatment
(Table 1).
4.3. Continuous Dopaminergic Stimulation. Since the intro-
duction of the concept of continuous dopaminergic stimu-
lation in the 1980s [3, 106–108], it has been realized that
constant delivery of dopaminergic drugs is associated with
a reduction in LID severity. Over the past decade, further
evidence has accumulated to support the notion that con-
tinuous stimulation of dopamine receptors may even reverse
some of the changes induced by chronic pulsatile levodopa
administration. The antidyskinetic response to this approach
is not immediate and it may take several weeks of continuous
infusion before becoming apparent. The initial pivotal study
using continuous delivery was published byMouradian et al.,
who used levodopa intravenously for 7–12 days to a small
group (n = 12) of patients with advanced PD [109]. They
found a progressive attenuation of LID and improvement
of the “on–oﬀ” fluctuations. Levodopa is too acid to be
delivered intravenously or subcutaneously in practice, a
problem by and large resolved with the development of
duodenal levodopa infusion. This has been used with clear
benefit to improve motor complications and quality of life
despite the obvious practical limitations [110–113]. Very
recently, the first double-blind, placebo controlled study
assessing the eﬀect of duodenal levodopa carried out in
North America has been disclosed. However, the technique
is complex, expensive, and potential long-term adverse
eﬀects are under debate, such as axonal polyneuropathy and
vitamin B complex deficiency [114, 115]. The infusion of
the duodenal levodopa gel, which also contains the dopa-
decarboxylase inhibitor carbidopa, is currently available only
in certain countries.
Further alternative strategies of oral intake were also
tested, such as controlled release levodopa/carbidopa for-
mulations, but they did not delay the onset of motor
complications [116]. The STRIDE-PD study, initiating lev-
odopa with entacapone, failed to reduce the frequency
or delay the onset of LID [117]; an inadequate dosing
schedule perturbing the putative continuous stimulation
expected to be achieved with this treatment and a bias in
the treatment group toward more severe disease have been
suggested as potential confounders [118]. IPX066 might be
soon available and it may be used to attain and maintain
therapeutic levodopa plasma concentrations with a potential
antidyskinetic eﬃcacy [119].
In line with continuous delivery procedures, dopamine
agonists that operate via the subcutaneous route, such as
lisuride and apomorphine, are associated with a reduction
in LID. The majority of trials used infusions during the
daytime but stopped at night to reduce the risk of severe
psychiatric complications. Stocchi et al. compared the long-
term incidence of dyskinesias in patients treated with
subcutaneous infusion of lisuride (plus supplementary oral
levodopa as needed) versus patients treated with standard
levodopa orally, and showed that patients receiving lisuride
infusions experienced a reduction in the incidence of
dyskinesia and motor fluctuations, compared with patients
receiving standard therapies [120]. The benefit lasted over
the 4 years of follow-up and this study also endorsed
earlier results indicating that continuous lisuride infusion
can be fairly well tolerated and beneficial for patients’ motor
complications, provided they have not previously developed
severe psychiatric complications [121, 122].
Similarly, Manson et al. reviewed their experience in
64 patients treated with subcutaneous apomorphine infu-
sions [123]. Forty-five patients were successfully converted
to monotherapy and discontinued all other dopaminergic
drugs during the daytime infusion. LIDwere reduced by 64%
in the monotherapy group compared to 30% in those on
polytherapy. Another retrospective evaluation over a 5-year
period of 82 patients receiving apomorphine obtained a sim-
ilar outcome [124], with average follow-up of ≈20 months,
5mg/h dose, and 14 hours/day duration. Patients improved
in severity of dyskinesia by 31% as assessed by the UPDRS
dyskinesia evaluation, injection-site adverse events being the
main reason for discontinuation of treatment. These results
confirmed that monotherapy with infusions of apomorphine
may reset peak-dose dyskinesia threshold in patients treated
with levodopa, while further reducing oﬀ-period disability.
Katzenschlager et al. prospectively assessed the antidyskinetic
eﬀect of continuous subcutaneous apomorphine using sub-
jective and objective measures and response to a levodopa
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Table 1
Practical suggestions for pharmacological management of LID
(1) The optimal therapeutic approach for LID is to try avoiding their development
(2) Start PD treatment with an agonist if possible, particularly in young onset patients
(3) Save levodopa as long as you can hold the patient’s requirements for daily life activities
(4) Adjust the drug schedule: reduce total daily doses and/or shorten the intake intervals
(5) Add amantadine 200–400mg/day
(6) Low doses of quetiapine or clozapine may be helpful
(7) Propose continuous drug delivery devices: duodenal levodopa/carbidopa gel or subcutaneous apomorphine
(8) For refractory cases, when indication is set by an expert and the risks are assumable by the patient, surgery is the treatment of choice
challenge [125]. By the sixth month the mean levodopa dose
had been reduced by 55% and the daily “oﬀ” time in patients’
diaries was reduced by 38%. Levodopa challenge showed a
reduction of 40–44% in the dyskinesia scores and patients’
self-assessment scores reflected these significant changes
positively. Overall, these results reinforce the concept that
replacement of oral short-acting antiparkinsonian drugs
with medication capable of providing more continuous
dopamine receptor stimulation may at least partially avoid
or reverse the sensitization process believed to mediate the
development of LID. In theory, therefore, therapy with
infusions capable of providing continuous dopaminergic
stimulation might be the pharmacological treatment of
choice for advanced PD patients. Nevertheless, the degree of
control of LID achieved with infusions is not complete in
many patients. Pharmacological tolerance appears in a large
proportion after some time on treatment. It occurs more
readily the more severe the underlying disease is, leading to
“oﬀ” episodes or exacerbation of diphasic dyskinesias. The
latter may cause a very troublesome dyskinetic status [122].
At this point, surgical treatment may still be the only and best
therapeutic option for a proportion of patients with severe
LID.
5. Surgical Treatments
The three main surgical targets for PD are the thalamus, GPi,
and STN. In this section we review the antidyskinetic eﬀect of
stereotactic surgery directed towards these 3 diﬀerent targets
using either ablative surgery or DBS.
5.1. The Thalamus and LID
5.1.1. Vim-Thalamotomy. During the 1960s the ventral lat-
eral nucleus (VL) of the thalamus was determined as the
best target to remove tremor in PD. This target was later
defined from physiology as the ventralis intermedius (Vim)
and it became established as the target of choice for tremor
of any origin [126–128]. Despite the thousands of thalamo-
tomies performed over the years, no formal and prospective
evaluation of the response of thalamic surgery against LID
has been reported in the literature. Some reports described
how the development of LID was prevented in patients
with a previous thalamotomy [129–132], others described
how the lesion improved tremor and also LID [133–135],
or the concept that LID improvement should be correlated
with daily levodopa reduction after surgery following tremor
suppression [136]. However, there are also reports where no
benefit was obtained with Vim-thalamotomy in patients with
LID [137].
The best study, which is somewhat an exception to the
above, is the observational paper published by Narabayashi
et al. [138]. These authors report an interesting and detailed
study of the eﬀect of thalamotomy against LID, dividing
the patients according to the thalamic target selected for
surgery. The patients subjected to lesions in the ventralis
oralis anterior nucleus (Voa) or posterior (Vop) prior to the
introduction of levodopa did not develop LID, but patients
subjected to Vim-thalamotomy for tremor did develop dysk-
inesias when levodopa was introduced as treatment [138].
The conclusion reached by Narabayashi et al. was that the
GPi-Voa/Vop pathway mediated LID and lesions restricted
to the Vim to treat tremor were not eﬀective against LID.
Interestingly, similar results were reported by Page et al.
in parkinsonian monkeys with LID induced by dopamine
agonists. Thalamotomy performed in the pallidal territory
removed LID, but lesions in the nigral or cerebellar terminal
territory of the thalamus had no antidyskinetic eﬀect [139].
5.1.2. Vim-DBS. The introduction of high frequency stimu-
lation coupled with stereotactic surgery supposed a marked
advance for patients with movement disorders. Vim-DBS
was initially performed as an additional contralateral treat-
ment to patients who had had a previous thalamotomy [140].
In a group of parkinsonian patients, Benabid et al. described
significant tremor improvement after Vim-DBS, which was
accompanied by inconsistent responses or no alleviation of
LID [141]. Similar results were obtained in other studies
[142–144]. In contrast, successful alleviation or suppression
of LID was described in association with a diﬀerent posi-
tioning of the electrode which supposedly impinges upon the
Vim and the Centromedian-parafascicular nucleus (CM-Pf)
[145–147]. However, a more recent study in MPTP treated
monkeys revealed that lesion of the CM-Pf had no eﬀect
against parkinsonian features or LID [148]. In conclusion,
the available data indicate that Vim lies outside the pathways
underlying LID and, accordingly, Vim’s surgery conveys no
eﬀect against LID.
Parkinson’s Disease 9
5.2. Surgery of the GPi and LID
5.2.1. Pallidotomy. Posteroventral pallidotomy was reintro-
duced as a treatment for PD, applying Leksell’s concepts, by
Laitinen et al. in 1992 [149]. The clinical response to pallidal
lesion included a significant benefit of the cardinal features
on the contralateral side and, unexpectedly according to
the basal ganglia model, a large impact against LID. Thus,
pallidotomy has been shown to portray a very significant
and long lasting eﬀect against peak dose dyskinesia, diphasic
dyskinesia, and also “oﬀ” period dystonia on the side con-
tralateral to the lesion. This antidyskinetic eﬀect is enduring
and long-lasting, for at least 10 years [150, 151], with a
benefit that occurred without a significant reduction in daily
levodopa dose.
5.2.2. GPi-DBS and LID. In the first multicentre DBS Coop-
erative Multicentre Study after GPi-DBS, patients showed a
76% reduction in LID severity (P < 0.0001) with no change
in levodopa doses at 1 and 4 years follow up [152, 153].
Longer follow-up (5-6 years) continued to show that GPi-
DBS maintained a significant improvement of LID with
a significant increase in “on” time without LID [154].
Levodopa was not significantly reduced compared with
baseline [155].
5.3. STN Surgery and LID
5.3.1. Subthalamotomy. The STN plays a capital role in the
pathophysiology of parkinsonian and dyskinetic states. This
anatomical target is typically considered a prodyskinetic
structure and classically avoided in patients with severe LID.
Subthalamotomy is performed on occasional patients, more
frequently in countries where DBS is not aﬀordable, with
fairly good general results [156].
Assessing the evolution of LID after subthalamotomy
is limited by the relatively reduced number of patients
reported, and by the variables in controlling some important
factors, such as levodopa dose pre- and postsurgery, surgical
procedure, lesion placement and volume. A recent analysis
described how in a group of 68 patients “peak dose dyskin-
esias” increased on the side contralateral to the lesion during
the first postoperative year but decreased after two to three
years, showing no significant change versus baseline at the
last assessment. In the ipsilateral side to the lesion, LID
increased significantly with the progressive increment of
levodopa suggesting that the operated side has had an anti-
dyskinetic eﬀect. Diphasic dyskinesias and “oﬀ” period
dystonia also improved significantly (P < 0.01) contralateral
to the lesion at 12th and 24th months after surgery [156].
5.3.2. STN-DBS. Bilateral STN-DBS is currently the surgical
procedure most often selected for PD patients given the
large impact against “oﬀ” medication severity and the
associated reduction in the daily levodopa dose [153, 157–
162]. STN-DBS has generally been associated with significant
reduction in LID, closely correlated with levodopa dosage
reduction. Subthalamic stimulation appears to improve the
whole spectrum of LID, such as peak dose dyskinesia (30%),
biphasic dyskinesia (50%), and “oﬀ” dystonia (90%) with
a 47% reduction in levodopa dosage as reported by Krack
et al. [157]. DBS-STN also increases “on” time without LID
and reduces “oﬀ” time periods [161–163]. After 5-6 years of
follow-up, LID scores were significantly improved by 83.3%
in total, with 75% reduction in dyskinesia duration and
100% drop of disability compared with baseline [153, 155,
161]. Levodopa reduction was also significantly reduced in
the long term compared with baseline preoperative data
(30%) [155]. In a survey of 38 studies involving 737 patients
treated in 34 neurosurgical centers, STN-DBS improved LID
assessed by UPDRS-IV scores 94% at 12 months in the on-
stimulation/“on” medication state in comparison with “on”
preoperative medication scores [163].
How STN-DBS may improve LID is not well understood
[164]. For most authors, LID improvement by STN-DBS
may be directly correlated with levodopa reduction [165–
169]. However, it is diﬃcult to interpret these studies,
because there are very few patients who maintained similar
levodopa equivalent doses after surgery. Thus, fluctuations
and LID disappeared in patients with levodopa withdrawal
postimplantation as Vingenhoerst et al. described, whereas
they persisted in those patients on medication 2 years after
surgery [167]. Similarly, another group reported that 1 year
after implantation, patients receiving levodopa displayed a
47% LID reduction, whereas the reduction was 90% of LID
in patients who did not receive levodopa (P < 0.003) [168].
On the other hand, the antidyskinetic response after STN-
DBS could be related with the eﬀect of continuous high
frequency stimulation, providing antidyskinetic eﬃcacy on
its own [170–172]. This may be supported by some instances
where improvement of LID occurred despite maintaining the
same daily dose of levodopa [170]. Thus, STN surgery could
induce a stable and continuous functional state with reduced
fluctuations in basal ganglia network, somehow mimicking
the eﬀect of continous dopaminergic stimulation.
Finally, it has also been suggested that the antidyskinetic
eﬀect of STN-DBS (as well as subthalamotomy) may be due
to an eﬀect on the dorsal border of the nucleus, reaching the
lenticularis fasciculus and zona incerta. In this context some
studies have suggested that the real subthalamic target may
be the region above the dorsal border of the nucleus [173–
175].
In conclusion, STN-DBS probably interferes with abnor-
mal discharge pattern in basal ganglia output nuclei associ-
ated with the parkinsonian condition, improving PD, and
permitting a reduction of chronic levodopa therapy. The
latter is likely responsible for the anti-LID eﬀect. On the
other hand, it is also possible that high frequency stimulation
of the STN could modify the patterns of neuronal firing and
the rhythms associated with LID having “per se” an anti-
dyskinetic eﬀect [176].
6. Conclusions
Most PD patients develop motor fluctuations and LID
during chronic evolution and on levodopa treatment. Motor
complications are directly related with disease progres-
sion and the eﬀects of chronic levodopa therapy. Once
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established, LID remains unabated throughout evolution.
Pharmacological management is not simple but in recent
years, the proportion of patients suﬀering severe LID has
declined considerably, mainly in relation with the use smaller
dose of levodopa. Surgical treatment has a potent anti-
dyskinetic eﬀect whose value has to be judged for every
particular patient against the risk. LID is no longer the major
cause of disability in PD patients nor a problem lacking
several treatment options.
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